Interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Prostate-specific antigen (PSA) is a key marker for monitoring prostate cancer treatment success.
• Temporary PSA increases, known as PSA bounce, can occur after brachytherapy.
• Distinguishing benign PSA bounce from treatment failure is clinically significant.

Purpose of the Study:

• To review the English literature on PSA bounce following prostate brachytherapy.
• To summarize current knowledge regarding the incidence, characteristics, and implications of PSA bounce.
• To highlight the importance of correctly diagnosing PSA bounce to prevent inappropriate salvage therapy.

Main Methods:

• Comprehensive literature search of English language studies on PSA bounce after brachytherapy.
• Inclusion of studies on low dose rate (LDR) and high dose rate (HDR) brachytherapy, as monotherapy or combined with external beam radiotherapy.
• Analysis of data related to PSA bounce definition, frequency, and influencing factors.

Main Results:

• PSA bounce is a frequent occurrence after prostate brachytherapy, observed in approximately 35% of patients.
• The incidence of PSA bounce increases significantly in younger patients, reaching up to 68% in those under 55.
• Factors such as age, sexual activity, radiation dose, prostate volume, and brachytherapy technique (LDR vs. HDR) may influence PSA bounce frequency.

Conclusions:

• Benign PSA bounce is a common and self-limited event after prostate brachytherapy.
• Accurate identification of PSA bounce is essential to avoid misdiagnosis of treatment failure.
• Proper recognition of PSA bounce can prevent unnecessary and potentially harmful salvage treatments for prostate cancer patients.